Nkarta (NASDAQ:NKTX) Given New $16.00 Price Target at Mizuho

Nkarta (NASDAQ:NKTX) had its target price lowered by Mizuho from $20.00 to $16.00 in a research note published on Thursday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other research analysts have also commented on the company. HC Wainwright decreased their price objective on Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Rodman & Renshaw began coverage on Nkarta in a research report on Wednesday, October 9th. They issued a “buy” rating and a $14.00 price objective for the company. Raymond James upgraded shares of Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 target price on the stock in a research report on Wednesday, August 14th. RODMAN&RENSHAW upgraded shares of Nkarta to a “strong-buy” rating in a research report on Wednesday, October 9th. Finally, Needham & Company LLC cut their price objective on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $15.00.

Nkarta Price Performance

Shares of NKTX stock traded down $0.04 during trading hours on Thursday, reaching $2.40. 200,263 shares of the company were exchanged, compared to its average volume of 1,141,407. The company has a market cap of $169.37 million, a price-to-earnings ratio of -1.30 and a beta of 0.86. The stock’s fifty day moving average is $3.86 and its two-hundred day moving average is $5.28. Nkarta has a fifty-two week low of $2.38 and a fifty-two week high of $16.24.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Meeder Asset Management Inc. acquired a new stake in Nkarta in the second quarter worth $26,000. GAMMA Investing LLC raised its stake in Nkarta by 1,887.0% during the 2nd quarter. GAMMA Investing LLC now owns 4,729 shares of the company’s stock worth $28,000 after buying an additional 4,491 shares during the period. Erste Asset Management GmbH acquired a new stake in Nkarta during the 3rd quarter worth $33,000. Forefront Analytics LLC bought a new position in Nkarta during the second quarter worth about $70,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in Nkarta in the first quarter valued at about $147,000. Institutional investors and hedge funds own 80.54% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.